MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
26.97
+0.56
+2.12%
Opening 13:05 11/09 EST
OPEN
26.79
PREV CLOSE
26.41
HIGH
27.36
LOW
25.96
VOLUME
457.76K
TURNOVER
--
52 WEEK HIGH
38.26
52 WEEK LOW
20.23
MARKET CAP
2.79B
P/E (TTM)
-26.9862
1D
5D
1M
3M
1Y
5Y
1D
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Simply Wall St · 2d ago
Beam Therapeutics: Buy Reiterated as Clinical Milestones Support Unchanged $80 Price Target
TipRanks · 3d ago
Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
Seeking Alpha · 4d ago
Beam Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 4d ago
Beam Therapeutics Price Target Cut to $51.00/Share From $55.00 by Guggenheim
Dow Jones · 4d ago
Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51
Benzinga · 4d ago
Beam Therapeutics price target lowered to $51 from $55 at Guggenheim
TipRanks · 4d ago
Beam Therapeutics Stock Faces Fresh Questions After Earnings Miss
Simply Wall St · 4d ago
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.